Consistently, with our previously published data, CCRL2 expression is significantly higher in MDS/AML cell lines with erythroleukemic features and TP53 mutations compared to AML cell lines derived from patients with de novo/TP53-wild type AML (Supplementary Fig. 1G). The gene discussed is TP53; the disease is acute myeloid leukemia.